Inozyme Pharma (NASDAQ:INZY) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Inozyme Pharma (NASDAQ:INZY) in a report released on Friday, Benzinga reports. The firm currently has a $14.00 price objective on the stock.

A number of other brokerages have also weighed in on INZY. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 price target (up from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. Stifel Nicolaus assumed coverage on Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $15.00 target price on shares of Inozyme Pharma in a research report on Monday, September 30th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inozyme Pharma presently has a consensus rating of “Buy” and an average target price of $16.14.

Inozyme Pharma Stock Down 2.4 %

Shares of NASDAQ:INZY traded down $0.12 during midday trading on Friday, reaching $4.79. The company’s stock had a trading volume of 189,896 shares, compared to its average volume of 195,843. Inozyme Pharma has a 12-month low of $2.69 and a 12-month high of $7.80. The firm has a market capitalization of $300.48 million, a P/E ratio of -3.28 and a beta of 1.51. The firm has a 50 day moving average of $5.29 and a 200-day moving average of $4.96. The company has a quick ratio of 9.84, a current ratio of 9.84 and a debt-to-equity ratio of 0.48.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). On average, research analysts anticipate that Inozyme Pharma will post -1.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of INZY. Deerfield Management Company L.P. Series C purchased a new stake in shares of Inozyme Pharma during the 2nd quarter valued at about $52,000. Meeder Asset Management Inc. purchased a new stake in Inozyme Pharma during the second quarter valued at approximately $68,000. Values First Advisors Inc. bought a new position in Inozyme Pharma in the second quarter worth approximately $76,000. SG Americas Securities LLC bought a new position in Inozyme Pharma in the third quarter worth approximately $81,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Inozyme Pharma during the 2nd quarter worth $84,000. Institutional investors own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.